ABSTRACT
Objective:
This study aimed to assess the relationship between sodium-glucose cotransporter-2 inhibitors and arrhythmias in individuals with type 2 diabetes mellitus who had a preserved ejection fraction.
Material and Methods:
The study comprised 70 random individuals who were admitted the University of Health Sciences Turkey, Antalya Training and Research Hospital internal medicine policlinic between October 2019 and May 2021 and who started empaglifozin. The patients’ electrocardiograms were obtained at the start and finish of the sixth month. At the start and after 6 months of empaglifozin treatment, echocardiography was done.
Results:
When basal and 6th month electrocardiograms were compared, significant changes were observed in P wave dispersion (0.0376±0.005- 0.0361±0.0049 p<0.007), QT interval dispersion (0.0389±0.0052-0.0376±0.0043 p<0.005) and QTc interval dispersion (0.051±0.0047- 0.049±0.0047 p<0.003).
Conclusions:
In our study, we concluded that empaglifozin has a direct and indirect beneficial effect on arrhythmia and does not have a harmful effect. Longer follow-up research will be guided by the results of our study.